Testing the Cerebraca Wafer With Temozolomide for Glioblastoma That Has Come Back
Official title: Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
Doctors are testing whether adding a wafer at surgery helps people whose glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary has come back.
Read our full plain-language summary
What the trial team says
This study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma. Cerebraca Wafer is intended for use in recurrent glioblastoma as an adjunct to surgery (followed by standard-of-care temozolomide), demonstrating potential to improve outcomes in this serious and life-threatening condition
Key facts
- Registry number
- NCT07349693
- Stage of testing
- Phase 2/Phase 3
- Conditions studied
- Recurrent Glioblastoma, IDH-Wildtype
Where it is running
This trial lists 1 site.
-
Rhode Island
- Legorreta Cancer Center Warren Alpert Medical School of Brown University (Providence)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.